| Symbol | CLLS |
|---|---|
| Name | CELLECTIS ROMAINVILLE |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 75013 France 8 rue de la Croix Jarry |
| Telephone | +33 (0)1 81 69 16 0 |
| Fax | — |
| — | |
| Website | http://www.cellectis.com |
| Incorporation | FR |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Euronext Paris |
| CIK | 0001627281 |
| Description | Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the bodys immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The companys gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology. Additional info from NASDAQ: |
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Read moreCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Read moreCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Read moreCellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
Read moreCellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Read moreCellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Read more